Yupelri is manufactured by Mylan N.V., now part of Viatris [1].
Who else makes Yupelri?
While Viatris is the current manufacturer, the development and initial approval of Yupelri involved collaborations. Sunovion Pharmaceuticals and Civitas Therapeutics were involved in its early stages [2].
What is Yupelri used for?
Yupelri is a medication used for the treatment of amyotrophic lateral sclerosis (ALS) [2]. It is administered via a nebulizer, which converts the liquid medication into a mist for inhalation [3].
How does Yupelri work?
Yupelri contains the active ingredient amantadine, which is thought to reduce the effects of glutamate in the brain. Glutamate is an excitatory neurotransmitter that can be present in excess in individuals with ALS, potentially contributing to motor neuron damage [2][4].
When did Yupelri become available?
Yupelri received FDA approval in September 2018 [2].
What are the side effects of Yupelri?
Common side effects reported with Yupelri include diarrhea, nausea, and upper respiratory tract infection [2][3]. More serious side effects can include swelling (edema) and liver enzyme elevations [3].
Are there alternatives to Yupelri for ALS?
Other treatments for ALS aim to slow disease progression or manage symptoms. Riluzole is another medication approved for ALS that may extend survival [5]. Supportive care, including physical therapy, occupational therapy, speech therapy, and nutritional support, is also crucial in managing ALS [6].
What is the patent status of Yupelri?
Drug patents are critical for manufacturers like Viatris, protecting their investment and market exclusivity. Information on Yupelri's specific patent expirations and any associated patent litigation can be found through specialized patent tracking resources [1]. For detailed information on drug patents, including those for Yupelri, DrugPatentWatch.com is a valuable resource [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.sunovion.com/our-pipeline/rd-pipeline/
[3] https://www. Yupelri.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434264/
[5] https://www.mayoclinic.org/diseases-conditions/amyotrophic-lateral-sclerosis/diagnosis-treatment/drc-20354304
[6] https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis